Antimicrobial Susceptibility Testing MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy Test Method / TechnologyBy Organism Type TestedBy ApplicationBy Sample/specimen TypeBy End UserBy Testing Site / Care SettingBy Distribution ChannelBy Testing Standard / Breakpoint Guideline
Full title & scope — all 9 axes with their segments
Antimicrobial Susceptibility Testing Market Size, Share & Industry Analysis, By Product Type (Automated & Semi-Automated AST Instruments, Reagents & Consumables, Manual & Non-Automated Instruments, Software & Data Management Systems, Testing Services), By Test Method / Technology (Disk Diffusion, Broth Microdilution / Macrodilution, Agar Dilution, Gradient Diffusion, Automated Broth Microdilution Systems, Genotypic / Molecular AST, MALDI-TOF MS-Based AST), By Organism Type Tested (Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, Antiviral Susceptibility Testing, Antiparasitic Susceptibility Testing), By Application (Clinical Diagnostics, Drug Discovery & Antimicrobial Development, Epidemiological & AMR Surveillance, Food, Water & Environmental Testing, Veterinary & Animal Health Testing), By Sample/specimen Type (Blood & Blood Culture, Urine, Respiratory Specimens, Wound, Tissue & Pus, Stool, Cerebrospinal & Other Sterile Body Fluids), By End User (Hospital & Clinical Laboratories, Independent Reference & Commercial Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Public Health & Government Agencies), By Testing Site / Care Setting (Centralized/Reference Laboratory Testing, Point-of-Care & Near-Patient Testing, Decentralized On-Site Hospital Lab Testing), By Distribution Channel (Direct Sales, Third-Party Distributors, Group Purchasing Organizations, Online/E-Procurement Platforms), By Testing Standard / Breakpoint Guideline (CLSI-Based Testing, EUCAST-Based Testing, Other National/Regional Standards), and Regional Forecast, 2026-2034
Last Updated: Oct 3, 2026Format: PDFReport ID: CDI-248799
TOC
Full table of contents for the published report, chapter by chapter.
Full chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
1.1Strategic Imperatives
1.2Definition
1.3Antimicrobial Susceptibility Testing Comparison By Segments
Chapter 2.Premium Insights
2.1Top 3 Trends to Watch
2.2Top 3 Strategies Followed by Major Players
2.3Top 3 Predictions by Contrive Datum Insights
2.4Top Investment Pockets
2.4.1Market Attractiveness Analysis, By Product Type
2.4.2Market Attractiveness Analysis, By Test Method / Technology
2.4.3Market Attractiveness Analysis, By Organism Type Tested
2.4.4Market Attractiveness Analysis, By Application
2.4.5Market Attractiveness Analysis, By Sample/specimen Type
2.4.6Market Attractiveness Analysis, By End User
2.4.7Market Attractiveness Analysis, By Testing Site / Care Setting
2.4.8Market Attractiveness Analysis, By Distribution Channel
2.4.9Market Attractiveness Analysis, By Testing Standard / Breakpoint Guideline
2.5Key Market Participants — Intensity Mapping
2.6Insights From Primary Respondents
Chapter 3.Market Definition
Chapter 4.Research Methodology
4.1Research Approach
4.1.1Research Programs / Design
4.1.2Market Size Estimation
4.2Data Sources
4.2.1Secondary Sources
4.2.1.1Preliminary Data Mining
4.2.2Primary Sources
4.2.2.1Statistical Model
4.2.2.2Data Triangulation
4.2.2.3Research Objective
4.3Flow Of Methodology
4.4Top-Down / Bottom-Up Approach
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
6.1Market Focus & Value Proposition
6.1.1Target Customers, Priority Markets, and Core Value Proposition
6.1.2Product Differentiation and Positioning Logic
6.2Commercial Model & Pricing Strategy
6.2.1Pricing Approach and Value Capture
6.2.2Contracting, Bundling, and Monetization Framework
6.3Channels, Sales & Partnerships
6.3.1Direct and Indirect Channel Strategy
6.3.2Sales Execution Model and Strategic Partnerships
6.4Marketing, Launch & Execution Roadmap
6.4.1Marketing and Demand Generation Approach
6.4.2Launch Sequencing and Rollout Plan
6.5Operational Readiness & Governance KPIs
6.5.1Supply Chain and Operational Preparedness
6.5.2Regulatory Considerations, Risks, and Performance Tracking
Chapter 7.Market Trends, Strategy & Dynamics
7.1Trends Overview
7.2Strategic Overview
7.3Market Drivers
7.4Market Restraints
7.5Market Opportunities
7.6Market Challenges
7.7Impact Analysis of Market Dynamics
Chapter 8.Porter's Five Forces
8.1Bargaining Power of Suppliers
8.2Bargaining Power of Buyers
8.3Threat of New Entrants
8.4Threat of Substitutes
8.5Competitive Rivalry
Chapter 9.PESTEL Analysis
9.1Political
9.2Economic
9.3Social
9.4Technological
9.5Environmental
9.6Legal
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
12.1Macro-Economic Factors Overview
12.2Forecast Factors — Relevance and Impact
Chapter 13.Market Cost Analysis
13.1Key Raw Materials Analysis
13.1.1Key Raw Materials
13.1.2Price Trend of Key Raw Materials
13.1.3Key Suppliers of Raw Materials
13.1.4Market Concentration Rate of Raw Materials
13.1.5Raw Materials
13.1.6Labor Cost
Chapter 14.Market Supply-Side Analysis
14.1Raw Materials
14.2Price Trends
14.3Industry Chain
14.4Raw Materials Sourcing
14.5Raw Materials Sources of Major Manufacturers
14.6Downstream Buyers
Chapter 15.Global Antimicrobial Susceptibility Testing Market Size & Projections, 2020–2034, Revenue (USD Billion)
15.1Global Antimicrobial Susceptibility Testing Market Size — Total
15.2Market Size, by Segment (By Product Type, By Test Method / Technology, By Organism Type Tested, By Application, By Sample/specimen Type, By End User, By Testing Site / Care Setting, By Distribution Channel, By Testing Standard / Breakpoint Guideline)
Chapter 16.Global Antimicrobial Susceptibility Testing Market Overview, By Product Type, 2020–2034, Revenue (USD Billion)
16.1Introduction
16.2Global Antimicrobial Susceptibility Testing Market Size, By Product Type, 2020–2034, Revenue (USD Billion)
16.3Global Antimicrobial Susceptibility Testing Market Share, By Product Type (%)
16.3.1Automated & Semi-Automated AST Instruments
16.3.1.1Market Size, By Automated & Semi-Automated AST Instruments, 2020–2034, Revenue (USD Billion)
16.3.1.2Automated & Semi-Automated AST Instruments Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
16.3.1.3Automated & Semi-Automated AST Instruments Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
16.3.1.4Automated & Semi-Automated AST Instruments Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
16.3.1.5Automated & Semi-Automated AST Instruments Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
16.3.1.6Automated & Semi-Automated AST Instruments Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
16.3.1.7Automated & Semi-Automated AST Instruments Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
16.3.1.8Automated & Semi-Automated AST Instruments Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
16.3.1.9Automated & Semi-Automated AST Instruments Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
16.3.2Reagents & Consumables
16.3.3Manual & Non-Automated Instruments (Incubators, Readers)
16.3.4Software & Data Management Systems
16.3.5Testing Services
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 16.3.1 (Automated & Semi-Automated AST Instruments).
Chapter 17.Global Antimicrobial Susceptibility Testing Market Overview, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
17.1Introduction
17.2Global Antimicrobial Susceptibility Testing Market Size, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
17.3Global Antimicrobial Susceptibility Testing Market Share, By Test Method / Technology (%)
17.3.1Disk Diffusion (Kirby-Bauer)
17.3.1.1Market Size, By Disk Diffusion (Kirby-Bauer), 2020–2034, Revenue (USD Billion)
17.3.1.2Disk Diffusion (Kirby-Bauer) Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
17.3.1.3Disk Diffusion (Kirby-Bauer) Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
17.3.1.4Disk Diffusion (Kirby-Bauer) Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
17.3.1.5Disk Diffusion (Kirby-Bauer) Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
17.3.1.6Disk Diffusion (Kirby-Bauer) Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
17.3.1.7Disk Diffusion (Kirby-Bauer) Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
17.3.1.8Disk Diffusion (Kirby-Bauer) Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
17.3.1.9Disk Diffusion (Kirby-Bauer) Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
17.3.2Broth Microdilution / Macrodilution
17.3.3Agar Dilution
17.3.4Gradient Diffusion (Etest)
17.3.5Automated Broth Microdilution Systems
17.3.6Genotypic / Molecular AST
17.3.7MALDI-TOF MS-Based AST
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 17.3.1 (Disk Diffusion (Kirby-Bauer)).
Chapter 18.Global Antimicrobial Susceptibility Testing Market Overview, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
18.1Introduction
18.2Global Antimicrobial Susceptibility Testing Market Size, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
18.3Global Antimicrobial Susceptibility Testing Market Share, By Organism Type Tested (%)
18.3.1Antibacterial Susceptibility Testing
18.3.1.1Market Size, By Antibacterial Susceptibility Testing, 2020–2034, Revenue (USD Billion)
18.3.1.2Antibacterial Susceptibility Testing Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
18.3.1.3Antibacterial Susceptibility Testing Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
18.3.1.4Antibacterial Susceptibility Testing Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
18.3.1.5Antibacterial Susceptibility Testing Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
18.3.1.6Antibacterial Susceptibility Testing Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
18.3.1.7Antibacterial Susceptibility Testing Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
18.3.1.8Antibacterial Susceptibility Testing Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
18.3.1.9Antibacterial Susceptibility Testing Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
18.3.2Antifungal Susceptibility Testing
18.3.3Antiviral Susceptibility Testing
18.3.4Antiparasitic Susceptibility Testing
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 18.3.1 (Antibacterial Susceptibility Testing).
Chapter 19.Global Antimicrobial Susceptibility Testing Market Overview, By Application, 2020–2034, Revenue (USD Billion)
19.1Introduction
19.2Global Antimicrobial Susceptibility Testing Market Size, By Application, 2020–2034, Revenue (USD Billion)
19.3Global Antimicrobial Susceptibility Testing Market Share, By Application (%)
19.3.1Clinical Diagnostics
19.3.1.1Market Size, By Clinical Diagnostics, 2020–2034, Revenue (USD Billion)
19.3.1.2Clinical Diagnostics Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
19.3.1.3Clinical Diagnostics Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
19.3.1.4Clinical Diagnostics Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
19.3.1.5Clinical Diagnostics Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
19.3.1.6Clinical Diagnostics Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
19.3.1.7Clinical Diagnostics Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
19.3.1.8Clinical Diagnostics Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
19.3.1.9Clinical Diagnostics Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
19.3.2Drug Discovery & Antimicrobial Development
19.3.3Epidemiological & AMR Surveillance
19.3.4Food
19.3.5Water & Environmental Testing
19.3.6Veterinary & Animal Health Testing
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 19.3.1 (Clinical Diagnostics).
Chapter 20.Global Antimicrobial Susceptibility Testing Market Overview, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
20.1Introduction
20.2Global Antimicrobial Susceptibility Testing Market Size, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
20.3Global Antimicrobial Susceptibility Testing Market Share, By Sample/specimen Type (%)
20.3.1Blood & Blood Culture
20.3.1.1Market Size, By Blood & Blood Culture, 2020–2034, Revenue (USD Billion)
20.3.1.2Blood & Blood Culture Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
20.3.1.3Blood & Blood Culture Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
20.3.1.4Blood & Blood Culture Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
20.3.1.5Blood & Blood Culture Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
20.3.1.6Blood & Blood Culture Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
20.3.1.7Blood & Blood Culture Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
20.3.1.8Blood & Blood Culture Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
20.3.1.9Blood & Blood Culture Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
20.3.2Urine
20.3.3Respiratory Specimens (Sputum/BAL)
20.3.4Wound
20.3.5Tissue & Pus
20.3.6Stool
20.3.7Cerebrospinal & Other Sterile Body Fluids
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 20.3.1 (Blood & Blood Culture).
Chapter 21.Global Antimicrobial Susceptibility Testing Market Overview, By End User, 2020–2034, Revenue (USD Billion)
21.1Introduction
21.2Global Antimicrobial Susceptibility Testing Market Size, By End User, 2020–2034, Revenue (USD Billion)
21.3Global Antimicrobial Susceptibility Testing Market Share, By End User (%)
21.3.1Hospital & Clinical Laboratories
21.3.1.1Market Size, By Hospital & Clinical Laboratories, 2020–2034, Revenue (USD Billion)
21.3.1.2Hospital & Clinical Laboratories Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
21.3.1.3Hospital & Clinical Laboratories Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
21.3.1.4Hospital & Clinical Laboratories Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
21.3.1.5Hospital & Clinical Laboratories Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
21.3.1.6Hospital & Clinical Laboratories Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
21.3.1.7Hospital & Clinical Laboratories Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
21.3.1.8Hospital & Clinical Laboratories Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
21.3.1.9Hospital & Clinical Laboratories Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
21.3.2Independent Reference & Commercial Laboratories
21.3.3Academic & Research Institutes
21.3.4Pharmaceutical & Biotechnology Companies
21.3.5Public Health & Government Agencies
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 21.3.1 (Hospital & Clinical Laboratories).
Chapter 22.Global Antimicrobial Susceptibility Testing Market Overview, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
22.1Introduction
22.2Global Antimicrobial Susceptibility Testing Market Size, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
22.3Global Antimicrobial Susceptibility Testing Market Share, By Testing Site / Care Setting (%)
22.3.1Centralized/Reference Laboratory Testing
22.3.1.1Market Size, By Centralized/Reference Laboratory Testing, 2020–2034, Revenue (USD Billion)
22.3.1.2Centralized/Reference Laboratory Testing Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
22.3.1.3Centralized/Reference Laboratory Testing Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
22.3.1.4Centralized/Reference Laboratory Testing Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
22.3.1.5Centralized/Reference Laboratory Testing Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
22.3.1.6Centralized/Reference Laboratory Testing Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
22.3.1.7Centralized/Reference Laboratory Testing Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
22.3.1.8Centralized/Reference Laboratory Testing Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
22.3.1.9Centralized/Reference Laboratory Testing Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
22.3.2Point-of-Care & Near-Patient Testing
22.3.3Decentralized On-Site Hospital Lab Testing
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 22.3.1 (Centralized/Reference Laboratory Testing).
Chapter 23.Global Antimicrobial Susceptibility Testing Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
23.1Introduction
23.2Global Antimicrobial Susceptibility Testing Market Size, By Distribution Channel, 2020–2034, Revenue (USD Billion)
23.3Global Antimicrobial Susceptibility Testing Market Share, By Distribution Channel (%)
23.3.1Direct Sales
23.3.1.1Market Size, By Direct Sales, 2020–2034, Revenue (USD Billion)
23.3.1.2Direct Sales Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
23.3.1.3Direct Sales Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
23.3.1.4Direct Sales Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
23.3.1.5Direct Sales Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
23.3.1.6Direct Sales Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
23.3.1.7Direct Sales Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
23.3.1.8Direct Sales Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
23.3.1.9Direct Sales Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
23.3.2Third-Party Distributors
23.3.3Group Purchasing Organizations (GPOs)
23.3.4Online/E-Procurement Platforms
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 23.3.1 (Direct Sales).
Chapter 24.Global Antimicrobial Susceptibility Testing Market Overview, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
24.1Introduction
24.2Global Antimicrobial Susceptibility Testing Market Size, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
24.3Global Antimicrobial Susceptibility Testing Market Share, By Testing Standard / Breakpoint Guideline (%)
24.3.1CLSI-Based Testing
24.3.1.1Market Size, By CLSI-Based Testing, 2020–2034, Revenue (USD Billion)
24.3.1.2CLSI-Based Testing Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
24.3.1.3CLSI-Based Testing Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
24.3.1.4CLSI-Based Testing Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
24.3.1.5CLSI-Based Testing Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
24.3.1.6CLSI-Based Testing Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
24.3.1.7CLSI-Based Testing Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
24.3.1.8CLSI-Based Testing Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
24.3.1.9CLSI-Based Testing Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
24.3.2EUCAST-Based Testing
24.3.3Other National/Regional Standards
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 24.3.1 (CLSI-Based Testing).
Chapter 25.Global Antimicrobial Susceptibility Testing Market Size — Segment Comparison
Chapter 26.Global Antimicrobial Susceptibility Testing Geography Overview, 2020–2034, Revenue (USD Billion)
26.1Revenue, By Geography, 2020–2034, Revenue (USD Billion)
26.2Share, By Geography, 2020–2034 (%)
26.3Share, By Geography Analysis, 2025, Market Share and CAGR
26.4Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Chapter 27.North America Antimicrobial Susceptibility Testing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
27.1Overview, 2020–2034
27.2Size and Projections, 2020–2034, Revenue (USD Billion)
27.2.1By Product Type, 2020–2034
27.2.2By Test Method / Technology, 2020–2034
27.2.3By Organism Type Tested, 2020–2034
27.2.4By Application, 2020–2034
27.2.5By Sample/specimen Type, 2020–2034
27.2.6By End User, 2020–2034
27.2.7By Testing Site / Care Setting, 2020–2034
27.2.8By Distribution Channel, 2020–2034
27.2.9By Testing Standard / Breakpoint Guideline, 2020–2034
27.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
27.3.1US
27.3.1.1US — Key Country Dynamics
27.3.1.2US — Regulatory Framework
27.3.1.3US — Competitive Scenario
27.3.1.4US — Market Overview, 2020–2034, Revenue (USD Billion)
27.3.1.5US — Market Size and Projections, 2020–2034, Revenue (USD Billion)
27.3.1.6US Market Overview, By Product Type, 2020–2034, Revenue (USD Billion)
27.3.1.7US Market Overview, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
27.3.1.8US Market Overview, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
27.3.1.9US Market Overview, By Application, 2020–2034, Revenue (USD Billion)
27.3.1.10US Market Overview, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
27.3.1.11US Market Overview, By End User, 2020–2034, Revenue (USD Billion)
27.3.1.12US Market Overview, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
27.3.1.13US Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
27.3.1.14US Market Overview, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
27.3.2Canada
27.3.3Mexico
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 27.3.1 (US).
Chapter 28.Europe Antimicrobial Susceptibility Testing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
28.1Overview, 2020–2034
28.2Size and Projections, 2020–2034, Revenue (USD Billion)
28.2.1By Product Type, 2020–2034
28.2.2By Test Method / Technology, 2020–2034
28.2.3By Organism Type Tested, 2020–2034
28.2.4By Application, 2020–2034
28.2.5By Sample/specimen Type, 2020–2034
28.2.6By End User, 2020–2034
28.2.7By Testing Site / Care Setting, 2020–2034
28.2.8By Distribution Channel, 2020–2034
28.2.9By Testing Standard / Breakpoint Guideline, 2020–2034
28.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
28.3.1Germany
28.3.1.1Germany — Key Country Dynamics
28.3.1.2Germany — Regulatory Framework
28.3.1.3Germany — Competitive Scenario
28.3.1.4Germany — Market Overview, 2020–2034, Revenue (USD Billion)
28.3.1.5Germany — Market Size and Projections, 2020–2034, Revenue (USD Billion)
28.3.1.6Germany Market Overview, By Product Type, 2020–2034, Revenue (USD Billion)
28.3.1.7Germany Market Overview, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
28.3.1.8Germany Market Overview, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
28.3.1.9Germany Market Overview, By Application, 2020–2034, Revenue (USD Billion)
28.3.1.10Germany Market Overview, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
28.3.1.11Germany Market Overview, By End User, 2020–2034, Revenue (USD Billion)
28.3.1.12Germany Market Overview, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
28.3.1.13Germany Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
28.3.1.14Germany Market Overview, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
28.3.2France
28.3.3Italy
28.3.4Spain
28.3.5UK
28.3.6Nordic Countries
28.3.7Benelux Union
28.3.8Rest of Europe
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 28.3.1 (Germany).
Chapter 29.Asia Pacific Antimicrobial Susceptibility Testing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
29.1Overview, 2020–2034
29.2Size and Projections, 2020–2034, Revenue (USD Billion)
29.2.1By Product Type, 2020–2034
29.2.2By Test Method / Technology, 2020–2034
29.2.3By Organism Type Tested, 2020–2034
29.2.4By Application, 2020–2034
29.2.5By Sample/specimen Type, 2020–2034
29.2.6By End User, 2020–2034
29.2.7By Testing Site / Care Setting, 2020–2034
29.2.8By Distribution Channel, 2020–2034
29.2.9By Testing Standard / Breakpoint Guideline, 2020–2034
29.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
29.3.1India
29.3.1.1India — Key Country Dynamics
29.3.1.2India — Regulatory Framework
29.3.1.3India — Competitive Scenario
29.3.1.4India — Market Overview, 2020–2034, Revenue (USD Billion)
29.3.1.5India — Market Size and Projections, 2020–2034, Revenue (USD Billion)
29.3.1.6India Market Overview, By Product Type, 2020–2034, Revenue (USD Billion)
29.3.1.7India Market Overview, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
29.3.1.8India Market Overview, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
29.3.1.9India Market Overview, By Application, 2020–2034, Revenue (USD Billion)
29.3.1.10India Market Overview, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
29.3.1.11India Market Overview, By End User, 2020–2034, Revenue (USD Billion)
29.3.1.12India Market Overview, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
29.3.1.13India Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
29.3.1.14India Market Overview, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
29.3.2Australia
29.3.3China
29.3.4China (Taiwan)
29.3.5Japan
29.3.6South Korea
29.3.7Southeast Asia
29.3.8Indonesia
29.3.9Thailand
29.3.10Malaysia
29.3.11Singapore
29.3.12Rest of Asia Pacific
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 29.3.1 (India).
Chapter 30.Latin America Antimicrobial Susceptibility Testing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
30.1Overview, 2020–2034
30.2Size and Projections, 2020–2034, Revenue (USD Billion)
30.2.1By Product Type, 2020–2034
30.2.2By Test Method / Technology, 2020–2034
30.2.3By Organism Type Tested, 2020–2034
30.2.4By Application, 2020–2034
30.2.5By Sample/specimen Type, 2020–2034
30.2.6By End User, 2020–2034
30.2.7By Testing Site / Care Setting, 2020–2034
30.2.8By Distribution Channel, 2020–2034
30.2.9By Testing Standard / Breakpoint Guideline, 2020–2034
30.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
30.3.1Brazil
30.3.1.1Brazil — Key Country Dynamics
30.3.1.2Brazil — Regulatory Framework
30.3.1.3Brazil — Competitive Scenario
30.3.1.4Brazil — Market Overview, 2020–2034, Revenue (USD Billion)
30.3.1.5Brazil — Market Size and Projections, 2020–2034, Revenue (USD Billion)
30.3.1.6Brazil Market Overview, By Product Type, 2020–2034, Revenue (USD Billion)
30.3.1.7Brazil Market Overview, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
30.3.1.8Brazil Market Overview, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
30.3.1.9Brazil Market Overview, By Application, 2020–2034, Revenue (USD Billion)
30.3.1.10Brazil Market Overview, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
30.3.1.11Brazil Market Overview, By End User, 2020–2034, Revenue (USD Billion)
30.3.1.12Brazil Market Overview, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
30.3.1.13Brazil Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
30.3.1.14Brazil Market Overview, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
30.3.2Argentina
30.3.3Rest of Latin America
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 30.3.1 (Brazil).
Chapter 31.Middle East and Africa Antimicrobial Susceptibility Testing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
31.1Overview, 2020–2034
31.2Size and Projections, 2020–2034, Revenue (USD Billion)
31.2.1By Product Type, 2020–2034
31.2.2By Test Method / Technology, 2020–2034
31.2.3By Organism Type Tested, 2020–2034
31.2.4By Application, 2020–2034
31.2.5By Sample/specimen Type, 2020–2034
31.2.6By End User, 2020–2034
31.2.7By Testing Site / Care Setting, 2020–2034
31.2.8By Distribution Channel, 2020–2034
31.2.9By Testing Standard / Breakpoint Guideline, 2020–2034
31.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
31.3.1GCC
31.3.1.1GCC — Key Country Dynamics
31.3.1.2GCC — Regulatory Framework
31.3.1.3GCC — Competitive Scenario
31.3.1.4GCC — Market Overview, 2020–2034, Revenue (USD Billion)
31.3.1.5GCC — Market Size and Projections, 2020–2034, Revenue (USD Billion)
31.3.1.6GCC Market Overview, By Product Type, 2020–2034, Revenue (USD Billion)
31.3.1.7GCC Market Overview, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
31.3.1.8GCC Market Overview, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
31.3.1.9GCC Market Overview, By Application, 2020–2034, Revenue (USD Billion)
31.3.1.10GCC Market Overview, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
31.3.1.11GCC Market Overview, By End User, 2020–2034, Revenue (USD Billion)
31.3.1.12GCC Market Overview, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
31.3.1.13GCC Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
31.3.1.14GCC Market Overview, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
31.3.2Egypt
31.3.3South Africa
31.3.4Rest of the Middle East & Africa
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 31.3.1 (GCC).
Chapter 32.Application / Use-Case Analysis
Chapter 33.Vendor Capability Scorecard
Chapter 34.Scenario Forecasts
34.1Bull-case Trajectory
34.2Base-case Trajectory
34.3Bear-case Trajectory
Chapter 35.Top 10 Key Clients of Top 10 Players
Chapter 36.Top 10 Suppliers
Chapter 37.Competitive Landscape
37.1bioMérieux SA
37.2Becton, Dickinson and Company (BD)
37.3Danaher Corporation (Beckman Coulter / Cepheid)
37.4Remel / Oxoid (formerly Thermo Fisher Scientific Microbiology, now an independent Astorg portfolio company)
37.5Bruker Corporation
37.6QIAGEN N.V.
37.7Accelerate Diagnostics, Inc.
37.8T2 Biosystems, Inc.
37.9Bio-Rad Laboratories, Inc.
37.10Merck KGaA (MilliporeSigma)
37.11Roche Diagnostics (F. Hoffmann-La Roche Ltd)
37.12Hardy Diagnostics
37.13Liofilchem S.r.l.
37.14Alifax S.r.l.
37.15HiMedia Laboratories Pvt. Ltd.
37.16Creative Diagnostics
37.17Selux Diagnostics, Inc.
37.18Autobio Diagnostics Co., Ltd.
37.19Werfen (Instrumentation Laboratory)
37.20Rapid Micro Biosystems, Inc.
37.21Diatron MI Zrt.
37.22Neogen Corporation
37.23Abbott Laboratories
37.24Coris BioConcept
Chapter 38.Partnerships & M&A
Chapter 39.Key Vendor Analysis
39.1bioMérieux SA
39.2Becton, Dickinson and Company (BD)
39.3Danaher Corporation (Beckman Coulter / Cepheid)
39.4Remel / Oxoid (formerly Thermo Fisher Scientific Microbiology, now an independent Astorg portfolio company)
39.5Bruker Corporation
39.6QIAGEN N.V.
39.7Accelerate Diagnostics, Inc.
39.8T2 Biosystems, Inc.
39.9Bio-Rad Laboratories, Inc.
39.10Merck KGaA (MilliporeSigma)
39.11Roche Diagnostics (F. Hoffmann-La Roche Ltd)
39.12Hardy Diagnostics
39.13Liofilchem S.r.l.
39.14Alifax S.r.l.
39.15HiMedia Laboratories Pvt. Ltd.
39.16Creative Diagnostics
39.17Selux Diagnostics, Inc.
39.18Autobio Diagnostics Co., Ltd.
39.19Werfen (Instrumentation Laboratory)
39.20Rapid Micro Biosystems, Inc.
39.21Diatron MI Zrt.
39.22Neogen Corporation
39.23Abbott Laboratories
39.24Coris BioConcept
Chapter 40.Marketing Strategy Analysis, Distributors & Traders
Chapter 41.Outlook of the Market
Chapter 42.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
Figure 2.1Top 3 Trends to Watch
Figure 2.4Top Investment Pockets
Figure 2.4.1Market Attractiveness Analysis, By Product Type
Figure 2.4.2Market Attractiveness Analysis, By Test Method / Technology
Figure 2.4.3Market Attractiveness Analysis, By Organism Type Tested
Figure 2.4.4Market Attractiveness Analysis, By Application
Figure 2.4.5Market Attractiveness Analysis, By Sample/specimen Type
Figure 2.4.6Market Attractiveness Analysis, By End User
Figure 2.4.7Market Attractiveness Analysis, By Testing Site / Care Setting
Figure 2.4.8Market Attractiveness Analysis, By Distribution Channel
Figure 2.4.9Market Attractiveness Analysis, By Testing Standard / Breakpoint Guideline
Figure 2.5Key Market Participants — Intensity Mapping
Figure 4.2.2.2Data Triangulation
Figure 4.3Flow Of Methodology
Figure 4.4Top-Down / Bottom-Up Approach
Figure 6.1.2Product Differentiation and Positioning Logic
Figure 16.3Global Antimicrobial Susceptibility Testing Market Share, By Product Type (%)
Figure 17.3Global Antimicrobial Susceptibility Testing Market Share, By Test Method / Technology (%)
Figure 18.3Global Antimicrobial Susceptibility Testing Market Share, By Organism Type Tested (%)
Figure 19.3Global Antimicrobial Susceptibility Testing Market Share, By Application (%)
Figure 20.3Global Antimicrobial Susceptibility Testing Market Share, By Sample/specimen Type (%)
Figure 21.3Global Antimicrobial Susceptibility Testing Market Share, By End User (%)
Figure 22.3Global Antimicrobial Susceptibility Testing Market Share, By Testing Site / Care Setting (%)
Figure 23.3Global Antimicrobial Susceptibility Testing Market Share, By Distribution Channel (%)
Figure 24.3Global Antimicrobial Susceptibility Testing Market Share, By Testing Standard / Breakpoint Guideline (%)
Figure 26.2Share, By Geography, 2020–2034 (%)
Figure 26.3Share, By Geography Analysis, 2025, Market Share and CAGR
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Table 1.3Antimicrobial Susceptibility Testing Comparison By Segments
Table 4.1.2Market Size Estimation
Table 15.1Global Antimicrobial Susceptibility Testing Market Size — Total
Table 15.2Market Size, by Segment (By Product Type, By Test Method / Technology, By Organism Type Tested, By Application, By Sample/specimen Type, By End User, By Testing Site / Care Setting, By Distribution Channel, By Testing Standard / Breakpoint Guideline)
Table 16.2Global Antimicrobial Susceptibility Testing Market Size, By Product Type, 2020–2034, Revenue (USD Billion)
Table 16.3.1.1Market Size, By Automated & Semi-Automated AST Instruments, 2020–2034, Revenue (USD Billion)
Table 16.3.1.2Automated & Semi-Automated AST Instruments Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 16.3.1.3Automated & Semi-Automated AST Instruments Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 16.3.1.4Automated & Semi-Automated AST Instruments Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 16.3.1.5Automated & Semi-Automated AST Instruments Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 16.3.1.6Automated & Semi-Automated AST Instruments Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 16.3.1.7Automated & Semi-Automated AST Instruments Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 16.3.1.8Automated & Semi-Automated AST Instruments Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 16.3.1.9Automated & Semi-Automated AST Instruments Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 17.2Global Antimicrobial Susceptibility Testing Market Size, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 17.3.1.1Market Size, By Disk Diffusion (Kirby-Bauer), 2020–2034, Revenue (USD Billion)
Table 17.3.1.2Disk Diffusion (Kirby-Bauer) Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
Table 17.3.1.3Disk Diffusion (Kirby-Bauer) Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 17.3.1.4Disk Diffusion (Kirby-Bauer) Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 17.3.1.5Disk Diffusion (Kirby-Bauer) Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 17.3.1.6Disk Diffusion (Kirby-Bauer) Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 17.3.1.7Disk Diffusion (Kirby-Bauer) Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 17.3.1.8Disk Diffusion (Kirby-Bauer) Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 17.3.1.9Disk Diffusion (Kirby-Bauer) Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 18.2Global Antimicrobial Susceptibility Testing Market Size, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 18.3.1.1Market Size, By Antibacterial Susceptibility Testing, 2020–2034, Revenue (USD Billion)
Table 18.3.1.2Antibacterial Susceptibility Testing Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
Table 18.3.1.3Antibacterial Susceptibility Testing Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 18.3.1.4Antibacterial Susceptibility Testing Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 18.3.1.5Antibacterial Susceptibility Testing Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 18.3.1.6Antibacterial Susceptibility Testing Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 18.3.1.7Antibacterial Susceptibility Testing Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 18.3.1.8Antibacterial Susceptibility Testing Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 18.3.1.9Antibacterial Susceptibility Testing Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 19.2Global Antimicrobial Susceptibility Testing Market Size, By Application, 2020–2034, Revenue (USD Billion)
Table 19.3.1.1Market Size, By Clinical Diagnostics, 2020–2034, Revenue (USD Billion)
Table 19.3.1.2Clinical Diagnostics Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
Table 19.3.1.3Clinical Diagnostics Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 19.3.1.4Clinical Diagnostics Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 19.3.1.5Clinical Diagnostics Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 19.3.1.6Clinical Diagnostics Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 19.3.1.7Clinical Diagnostics Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 19.3.1.8Clinical Diagnostics Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 19.3.1.9Clinical Diagnostics Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 20.2Global Antimicrobial Susceptibility Testing Market Size, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 20.3.1.1Market Size, By Blood & Blood Culture, 2020–2034, Revenue (USD Billion)
Table 20.3.1.2Blood & Blood Culture Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
Table 20.3.1.3Blood & Blood Culture Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 20.3.1.4Blood & Blood Culture Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 20.3.1.5Blood & Blood Culture Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 20.3.1.6Blood & Blood Culture Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 20.3.1.7Blood & Blood Culture Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 20.3.1.8Blood & Blood Culture Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 20.3.1.9Blood & Blood Culture Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 21.2Global Antimicrobial Susceptibility Testing Market Size, By End User, 2020–2034, Revenue (USD Billion)
Table 21.3.1.1Market Size, By Hospital & Clinical Laboratories, 2020–2034, Revenue (USD Billion)
Table 21.3.1.2Hospital & Clinical Laboratories Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
Table 21.3.1.3Hospital & Clinical Laboratories Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 21.3.1.4Hospital & Clinical Laboratories Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 21.3.1.5Hospital & Clinical Laboratories Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 21.3.1.6Hospital & Clinical Laboratories Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 21.3.1.7Hospital & Clinical Laboratories Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 21.3.1.8Hospital & Clinical Laboratories Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 21.3.1.9Hospital & Clinical Laboratories Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 22.2Global Antimicrobial Susceptibility Testing Market Size, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 22.3.1.1Market Size, By Centralized/Reference Laboratory Testing, 2020–2034, Revenue (USD Billion)
Table 22.3.1.2Centralized/Reference Laboratory Testing Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
Table 22.3.1.3Centralized/Reference Laboratory Testing Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 22.3.1.4Centralized/Reference Laboratory Testing Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 22.3.1.5Centralized/Reference Laboratory Testing Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 22.3.1.6Centralized/Reference Laboratory Testing Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 22.3.1.7Centralized/Reference Laboratory Testing Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 22.3.1.8Centralized/Reference Laboratory Testing Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 22.3.1.9Centralized/Reference Laboratory Testing Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 23.2Global Antimicrobial Susceptibility Testing Market Size, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 23.3.1.1Market Size, By Direct Sales, 2020–2034, Revenue (USD Billion)
Table 23.3.1.2Direct Sales Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
Table 23.3.1.3Direct Sales Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 23.3.1.4Direct Sales Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 23.3.1.5Direct Sales Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 23.3.1.6Direct Sales Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 23.3.1.7Direct Sales Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 23.3.1.8Direct Sales Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 23.3.1.9Direct Sales Size and Projections, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 24.2Global Antimicrobial Susceptibility Testing Market Size, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 24.3.1.1Market Size, By CLSI-Based Testing, 2020–2034, Revenue (USD Billion)
Table 24.3.1.2CLSI-Based Testing Size and Projections, By Product Type, 2020–2034, Revenue (USD Billion)
Table 24.3.1.3CLSI-Based Testing Size and Projections, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 24.3.1.4CLSI-Based Testing Size and Projections, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 24.3.1.5CLSI-Based Testing Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 24.3.1.6CLSI-Based Testing Size and Projections, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 24.3.1.7CLSI-Based Testing Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 24.3.1.8CLSI-Based Testing Size and Projections, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 24.3.1.9CLSI-Based Testing Size and Projections, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 26.1Revenue, By Geography, 2020–2034, Revenue (USD Billion)
Table 26.4Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 27.1Overview, 2020–2034
Table 27.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 27.2.1By Product Type, 2020–2034
Table 27.2.2By Test Method / Technology, 2020–2034
Table 27.2.3By Organism Type Tested, 2020–2034
Table 27.2.4By Application, 2020–2034
Table 27.2.5By Sample/specimen Type, 2020–2034
Table 27.2.6By End User, 2020–2034
Table 27.2.7By Testing Site / Care Setting, 2020–2034
Table 27.2.8By Distribution Channel, 2020–2034
Table 27.2.9By Testing Standard / Breakpoint Guideline, 2020–2034
Table 27.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 27.3.1.4US — Market Overview, 2020–2034, Revenue (USD Billion)
Table 27.3.1.5US — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 27.3.1.6US Market Overview, By Product Type, 2020–2034, Revenue (USD Billion)
Table 27.3.1.7US Market Overview, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 27.3.1.8US Market Overview, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 27.3.1.9US Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 27.3.1.10US Market Overview, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 27.3.1.11US Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 27.3.1.12US Market Overview, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 27.3.1.13US Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 27.3.1.14US Market Overview, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 28.1Overview, 2020–2034
Table 28.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 28.2.1By Product Type, 2020–2034
Table 28.2.2By Test Method / Technology, 2020–2034
Table 28.2.3By Organism Type Tested, 2020–2034
Table 28.2.4By Application, 2020–2034
Table 28.2.5By Sample/specimen Type, 2020–2034
Table 28.2.6By End User, 2020–2034
Table 28.2.7By Testing Site / Care Setting, 2020–2034
Table 28.2.8By Distribution Channel, 2020–2034
Table 28.2.9By Testing Standard / Breakpoint Guideline, 2020–2034
Table 28.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 28.3.1.4Germany — Market Overview, 2020–2034, Revenue (USD Billion)
Table 28.3.1.5Germany — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 28.3.1.6Germany Market Overview, By Product Type, 2020–2034, Revenue (USD Billion)
Table 28.3.1.7Germany Market Overview, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 28.3.1.8Germany Market Overview, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 28.3.1.9Germany Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 28.3.1.10Germany Market Overview, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 28.3.1.11Germany Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 28.3.1.12Germany Market Overview, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 28.3.1.13Germany Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 28.3.1.14Germany Market Overview, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 29.1Overview, 2020–2034
Table 29.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 29.2.1By Product Type, 2020–2034
Table 29.2.2By Test Method / Technology, 2020–2034
Table 29.2.3By Organism Type Tested, 2020–2034
Table 29.2.4By Application, 2020–2034
Table 29.2.5By Sample/specimen Type, 2020–2034
Table 29.2.6By End User, 2020–2034
Table 29.2.7By Testing Site / Care Setting, 2020–2034
Table 29.2.8By Distribution Channel, 2020–2034
Table 29.2.9By Testing Standard / Breakpoint Guideline, 2020–2034
Table 29.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 29.3.1.4India — Market Overview, 2020–2034, Revenue (USD Billion)
Table 29.3.1.5India — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 29.3.1.6India Market Overview, By Product Type, 2020–2034, Revenue (USD Billion)
Table 29.3.1.7India Market Overview, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 29.3.1.8India Market Overview, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 29.3.1.9India Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 29.3.1.10India Market Overview, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 29.3.1.11India Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 29.3.1.12India Market Overview, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 29.3.1.13India Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 29.3.1.14India Market Overview, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 30.1Overview, 2020–2034
Table 30.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 30.2.1By Product Type, 2020–2034
Table 30.2.2By Test Method / Technology, 2020–2034
Table 30.2.3By Organism Type Tested, 2020–2034
Table 30.2.4By Application, 2020–2034
Table 30.2.5By Sample/specimen Type, 2020–2034
Table 30.2.6By End User, 2020–2034
Table 30.2.7By Testing Site / Care Setting, 2020–2034
Table 30.2.8By Distribution Channel, 2020–2034
Table 30.2.9By Testing Standard / Breakpoint Guideline, 2020–2034
Table 30.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 30.3.1.4Brazil — Market Overview, 2020–2034, Revenue (USD Billion)
Table 30.3.1.5Brazil — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 30.3.1.6Brazil Market Overview, By Product Type, 2020–2034, Revenue (USD Billion)
Table 30.3.1.7Brazil Market Overview, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 30.3.1.8Brazil Market Overview, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 30.3.1.9Brazil Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 30.3.1.10Brazil Market Overview, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 30.3.1.11Brazil Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 30.3.1.12Brazil Market Overview, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 30.3.1.13Brazil Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 30.3.1.14Brazil Market Overview, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Table 31.1Overview, 2020–2034
Table 31.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 31.2.1By Product Type, 2020–2034
Table 31.2.2By Test Method / Technology, 2020–2034
Table 31.2.3By Organism Type Tested, 2020–2034
Table 31.2.4By Application, 2020–2034
Table 31.2.5By Sample/specimen Type, 2020–2034
Table 31.2.6By End User, 2020–2034
Table 31.2.7By Testing Site / Care Setting, 2020–2034
Table 31.2.8By Distribution Channel, 2020–2034
Table 31.2.9By Testing Standard / Breakpoint Guideline, 2020–2034
Table 31.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 31.3.1.4GCC — Market Overview, 2020–2034, Revenue (USD Billion)
Table 31.3.1.5GCC — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 31.3.1.6GCC Market Overview, By Product Type, 2020–2034, Revenue (USD Billion)
Table 31.3.1.7GCC Market Overview, By Test Method / Technology, 2020–2034, Revenue (USD Billion)
Table 31.3.1.8GCC Market Overview, By Organism Type Tested, 2020–2034, Revenue (USD Billion)
Table 31.3.1.9GCC Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 31.3.1.10GCC Market Overview, By Sample/specimen Type, 2020–2034, Revenue (USD Billion)
Table 31.3.1.11GCC Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 31.3.1.12GCC Market Overview, By Testing Site / Care Setting, 2020–2034, Revenue (USD Billion)
Table 31.3.1.13GCC Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Table 31.3.1.14GCC Market Overview, By Testing Standard / Breakpoint Guideline, 2020–2034, Revenue (USD Billion)
Scope
Questions This Report Answers
6 questions01
What is the market size and growth rate, globally and by region?
02
How is the market segmented, and which segments lead?
03
Which regions and countries are covered, and how do they compare?
04
What are the key drivers, restraints, opportunities and challenges?
05
Who are the leading companies operating in this market?
06
What trends are expected to shape the market through the forecast period?
Questions
Frequently Asked Questions
01What is the Antimicrobial Susceptibility Testing Market projected to reach?
USD 9.68 USD Billion by 2034, CAGR 8.5%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 40.2% of global revenue through 2034.
05Which segment leads the market?
Reagents & Consumables is the largest line by product type, at 38.1% of revenue in 2025.
06Who are the key companies profiled?
bioMérieux SA, Becton, Dickinson and Company (BD), Danaher Corporation (Beckman Coulter / Cepheid), Remel / Oxoid (formerly Thermo Fisher Scientific Microbiology, now an independent Astorg portfolio company), Bruker Corporation, QIAGEN N.V., Accelerate Diagnostics, Inc., T2 Biosystems, Inc., Bio-Rad Laboratories, Inc., Merck KGaA (MilliporeSigma), Roche Diagnostics (F. Hoffmann-La Roche Ltd), Hardy Diagnostics, Liofilchem S.r.l., Alifax S.r.l., HiMedia Laboratories Pvt. Ltd., Creative Diagnostics, Selux Diagnostics, Inc., Autobio Diagnostics Co., Ltd., Werfen (Instrumentation Laboratory), Rapid Micro Biosystems, Inc., Diatron MI Zrt., Neogen Corporation, Abbott Laboratories, Coris BioConcept. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
425+
Dedicated research analysts
1,200+
Reports published
Why CDI
Why choose CDI
Data triangulated across primary and secondary sources
Complimentary analyst call included with every purchase
Custom data cuts and post-purchase support available
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.
Explore
Related Reports
Medical Devices
Immunoassay Market
USD 60.95 Bn by 2034, CAGR 6.82%
Medical Devices
Cancer Biomakers Market
USD 63.5 Bn by 2034, CAGR 10.44%
Medical Devices
Klebsiella Testing Market
USD 731 Mn by 2034, CAGR 11.68%
Medical Devices
Cell Cryopreservation Consumables Market
USD 13.29 Bn by 2034, CAGR 11.11%
Pharmaceuticals & Biotech
Bio Process Technology Market
USD 82.3 Bn by 2034, CAGR 10.18%
Medical Devices
Monogenetic Disorders Testing Market
USD 1692.1 Mn by 2034, CAGR 11.37%